Active ingredientSelumetinibCat. No. P-S030-001CAS 606143-52-6Family · Pharmaceutical analytical standards
Selumetinib
A selective inhibitor of the MEK1 and MEK2 kinases, approved in the United States in 2020 and in Europe in 2021 for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1. This family brings together the active ingredient and other impurities.
Did you know?It was the first medicine approved in the United States for this rare genetic disease; in 2025 the approval was extended to adults as well.
Go to the active ingredient →Active ingredientSelumetinibCat. No. P-S030-001CAS 606143-52-6
Active ingredientSelumetinib SulfateCat. No. P-S030-002CAS 943332-08-9
ImpuritySelumetinib Impurity 1Cat. No. P-S030-003CAS 606144-04-1
ImpuritySelumetinib Sulfonic Acid ImpurityCat. No. P-S030-004No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.